← All trials
NCT00276731
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 1995
- Primary completion
- —
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- Children's Cancer and Leukaemia GroupLead sponsor
- Yale UniversityOfficial
- Moorgreen Hospital, SouthamptonOfficial
- Mercy Regional Cancer Center at Mercy Medical CenterOfficial
- University of GlasgowStudy chair
- Newcastle UniversityOfficial
- University of Alabama, BirminghamOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.